BANZEL
Banzel (rufinamide) is an antiepileptic medication indicated for the adjunctive treatment of seizures. It is used specifically for patients diagnosed with Lennox-Gastaut Syndrome, a severe form of epilepsy. The medication is approved for use in adults as well as pediatric patients one year of age and older.
How BANZEL Works
The precise mechanism by which rufinamide exerts its antiepileptic effect is unknown. Research suggests the drug functions by modulating sodium channel activity, specifically by prolonging the inactive state of the channel. This action slows the recovery of sodium channels and limits the sustained repetitive firing of action potentials in the neurons.
Details
- Status
- Prescription
- First Approved
- 2008-11-14
- Routes
- ORAL
- Dosage Forms
- SUSPENSION, TABLET
BANZEL Approval History
What BANZEL Treats
2 indicationsBANZEL is approved for 2 conditions since its original approval in 2008. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Lennox-Gastaut Syndrome
- Seizures
Drugs Similar to BANZEL
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
BANZEL FDA Label Details
ProIndications & Usage
FDA Label (PDF)1 I NDICATIONS AND USAGE BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome in pediatric patients 1 year of age and older and in adults. BANZEL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in pediatric patients 1 year of age and older, and in adults
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.